Drugs / doxorubicon
last change Oct 2014 re-read 2 minutes ago

doxorubicon

also known as Myocet
Developed for
HER2 positive breast carcinoma
Investigated by
Cancer Trials Ireland

Trials 1 · a red edge is where a trial was stopped

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT01495884 Mar 2011 → Oct 2014 HER2 positive breast carcinoma Cancer Trials Ireland Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as doxorubicon ClinicalTrials.gov intervention name — accepted as the source's own label NCT01495884
Known as Myocet “non-pegylated liposomal doxorubicon (Myocet™)” NCT01495884